Alpha Cognition announces US launch of ZUNVEYL (Benzgalantamine) for the treatment of mild to moderate Alzheimer’s disease
March 18 2025: Alpha Cognition Inc. today announced the official launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade.
The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease. Our team has worked relentlessly to bring this treatment to market — from building out an industry-leading infrastructure to hiring a top notch sales team — all in record time. I’m incredibly proud of the dedication and expertise of our team, and we are excited to partner with healthcare professionals to ensure that patients receive the care they deserve.” Lauren D’Angelo, Chief Operating Officer and Chief Commercial Officer of Alpha Cognition.
ZUNVEYL is designed to provide a differentiated treatment option for patients with mild to moderate Alzheimer’s disease, offering an alternative for those who may have limited options. With the commercial launch now underway, Alpha Cognition is engaging with healthcare providers, payers, and caregivers to support patient access and education across the US.
To learn more about ZUNVEYL, visit ZUNVEYL.com.
